Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
EBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Seres Therapeutics (MCRB) Other Operating Expenses (2016 - 2025)

Historic Other Operating Expenses for Seres Therapeutics (MCRB) over the last 6 years, with Q3 2025 value amounting to $736000.0.

  • Seres Therapeutics' Other Operating Expenses changed N/A to $736000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $6.6 million, marking a year-over-year change of. This contributed to the annual value of $3.5 million for FY2024, which is N/A changed from last year.
  • Seres Therapeutics' Other Operating Expenses amounted to $736000.0 in Q3 2025.
  • In the past 5 years, Seres Therapeutics' Other Operating Expenses registered a high of $3.6 million during Q1 2023, and its lowest value of -$346000.0 during Q4 2022.
  • Moreover, its 5-year median value for Other Operating Expenses was $1.0 million (2022), whereas its average is $1.3 million.
  • In the last 5 years, Seres Therapeutics' Other Operating Expenses crashed by 15719.01% in 2022 and then surged by 87712.18% in 2023.
  • Quarter analysis of 5 years shows Seres Therapeutics' Other Operating Expenses stood at $605000.0 in 2021, then plummeted by 157.19% to -$346000.0 in 2022, then soared by 708.67% to $2.1 million in 2023, then soared by 67.71% to $3.5 million in 2024, then crashed by 79.16% to $736000.0 in 2025.
  • Its last three reported values are $736000.0 in Q3 2025, $185000.0 for Q2 2025, and $2.2 million during Q1 2025.